EMA recommends Glaxo's melanoma med Mekinist; Merck forms digital partnership to track vaccine use;

> The European Medicines Agency (EMA) has recommended approval of GlaxoSmithKline's ($GSK) Mekinist as a treatment for melanoma. Release

> Roche ($RHHBY) has nabbed EU approval for a new subcutaneous formulation of rheumatoid arthritis treatment RoActemra. Release

> Augé Reichenberg has joined McCann HumanCare as its executive creative director. Release

> Merck ($MRK) has partnered with electronic health record provider Practice Fusion to help doctors track whether patients are up-to-date on their vaccines. More

> The FDA is reviewing the risks and side effects associated with Pfizer's ($PFE) anti-smoking drug Chantix. More

> Remarketing and consulting specialist Generic Pharma 2.0 have formed a strategic alliance. Report

> Philadelphia's Star Group has merged with healthcare marketing agencies Vox Medica and Calcium NYC. More

And Finally... How should Sun Pharma, the new owner of troubled Ranbaxy, handle its tarnished name? More (sub. req.)

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Klick Health has debuted its annual holiday video message for pharma clients and potential employees with a message about being kind.

The Tecentriq-chemo approval is the second one for the Roche PD-L1 drug in front-line NSCLC, following an OK for a regimen that also contains Avastin.